Can Commun Dis Rep. 1993 Jul 30;19(14):104-15.
The following recommendations on hepatitis B vaccine from NACI will appear in the 4th edition of the Canadian Immunization Guide scheduled for publication in autumn 1993. They contain updated information on the epidemiology of hepatitis B in Canada and response to hepatitis B vaccine. In addition to vaccinating targeted high-risk populations, routine childhood immunization is now recommended although details on the preferred target age group and schedule are not yet finalized. There are some changes to the sections on pre-exposure immunization, post-exposure management, routine boosters (no longer needed), and post-vaccination serology. Finally, the statement incorporates the new vaccine dosages for infants and children for Merck Sharp and Dohme's Recombivax HB, approved January 1992, and SmithKline Beecham's Engerix-B, approved September 1992.
加拿大国家免疫咨询委员会（NACI）关于乙肝疫苗的以下建议将出现在定于1993年秋季出版的《加拿大免疫指南》第4版中。这些建议包含了加拿大乙肝流行病学的最新信息以及对乙肝疫苗的反应。除了为目标高危人群接种疫苗外，现在还建议进行常规儿童免疫接种，不过关于首选目标年龄组和接种程序的细节尚未最终确定。暴露前免疫、暴露后管理、常规加强免疫（不再需要）以及接种后血清学等部分有一些变化。最后，该声明纳入了1992年1月批准的默克雪兰诺公司的重组酵母乙肝疫苗（Recombivax HB）以及1992年9月批准的史克必成公司的乙肝重组疫苗（Engerix - B）针对婴儿和儿童的新疫苗剂量。
